Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS8 | O00214 | 5/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | CD209 | Q9NNX6 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | OGA | O60502 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.36 |
| ▸ | PYGB | P11216 | 1/20 | 0.36 |
| ▸ | FGF1 | P05230 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13482776 | 1.00 | LGALS8 (0.43) | LGALS8L3MBTL1MAPTCD209GAA | |
| SCHEMBL20033536 | 1.00 | LGALS8 (0.43) | LGALS8L3MBTL1MAPTCD209GAA | |
| SCHEMBL17256295 | 1.00 | LGALS8 (0.43) | LGALS8L3MBTL1MAPTCD209GAA | |
| SCHEMBL13483316 | 1.00 | LGALS8 (0.43) | LGALS8L3MBTL1MAPTCD209GAA | |
| SCHEMBL14864297 | 1.00 | LGALS8 (0.43) | LGALS8L3MBTL1MAPTCD209GAA | |
| SCHEMBL18723048 | 1.00 | LGALS8 (0.43) | LGALS8L3MBTL1MAPTCD209GAA | |
| SCHEMBL16504207 | 1.00 | LGALS8 (0.43) | LGALS8L3MBTL1MAPTCD209GAA | |
| SCHEMBL17154136 | 0.88 | LGALS8 (0.39) | LGALS8L3MBTL1MAPTCD209OGA | |
| SCHEMBL14802349 | 0.88 | LGALS8 (0.39) | LGALS8L3MBTL1MAPTCD209OGA | |
| SCHEMBL15293443 | 0.88 | LGALS8 (0.39) | LGALS8L3MBTL1MAPTCD209OGA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12605451-B2 | Targeted plasma protein degradation | NOVARTIS AG (CH) | 2026-04-21 | — | — | US | disclosed |
| US-20230398224-A1 | TARGETED PLASMA PROTEIN DEGRADATION | NOVARTIS AG (CH) | 2023-12-14 | — | — | US | disclosed |
| US-20230398224-A1 | TARGETED PLASMA PROTEIN DEGRADATION | NOVARTIS AG (CH) | 2023-12-14 | — | — | US | disclosed |
| EP-4100064-A1 | TARGETED PLASMA PROTEIN DEGRADATION | Novartis AG (CH) | 2022-12-14 | — | — | EP | disclosed |
| WO-2021156792-A1 | TARGETED PLASMA PROTEIN DEGRADATION | NOVARTIS AG (CH) | 2021-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12605451-B2 | Targeted plasma protein degradation | M6PR, ASGR1, IGF2R | LGALS8 267/4885L3MBTL1 424/4885MAPT 1302/4885 |
| US-20230398224-A1 | TARGETED PLASMA PROTEIN DEGRADATION | M6PR, ASGR1, IGF2R | LGALS8 295/4885L3MBTL1 910/4885MAPT 2059/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.